Role of maternal tryptophan metabolism in allergic diseases in the offspring
Authors:
- Hui Xing LauHLHui Xing Lau
- Sarah El‐HeisSESarah El‐Heis
- Qai Ven YapQYQai Ven Yap
- Yiong Huak ChanYCYiong Huak Chan
- Cheryl Pei Ting TanCTCheryl Pei Ting Tan
- Neerja KarnaniNKNeerja Karnani
- Karen Mei Ling TanKTKaren Mei Ling Tan
- Elizabeth Huiwen ThamETElizabeth Huiwen Tham
- Anne Eng Neo GohAGAnne Eng Neo Goh
- Oon Hoe TeohOTOon Hoe Teoh
- Kok Hian TanKTKok Hian Tan
- Johan Gunnar ErikssonJEJohan Gunnar Eriksson
- 24 June 2021
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 51 (10) , 1346-1360
Abstract
Background: Nicotinamide (vitamin B3) is a metabolite of tryptophan and dietary precursor of enzymes involved in many regulatory processes, which may influence fetal immune development.Objective: We examined whether maternal plasma concentrations of nicotinamide, tryptophan or nine related tryptophan metabolites during pregnancy were associated with the risk of development of infant eczema, wheeze, rhinitis or allergic sensitization.Methods: In the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) study, we analysed the associations between maternal plasma levels of nicotinamide, tryptophan and tryptophan metabolites at 26–28 weeks of gestation and allergic outcomes collected through interviewer‐administered questionnaires at multiple time‐points and skin prick testing to egg, milk, peanut and mites at age 18 months. Multivariate analysis was undertaken adjusting for all metabolites measured and separately adjusting for relevant demographic and environmental exposures. Analyses were also adjusted for multiple comparisons using the false discovery method.Results: Tryptophan metabolites were evaluated in 976/1247 (78%) women enrolled in GUSTO. In multivariate analysis including all metabolites, maternal plasma 3‐hydrokynurenine was associated with increased allergic sensitization at 18 months (AdjRR 2.6, 95% CI 1.3–5.2 for highest quartile) but the association with nicotinamide was not significant (AdjRR 1.8, 95% CI 0.9–3.6). In analysis adjusting for other exposures, both 3‐hydrokynurenine and nicotinamide were associated with increased allergic sensitization (AdjRR 2.0, 95% CI 1.1–3.6 for both metabolites). High maternal plasma nicotinamide was associated with increased infant eczema diagnosis by 6 and 12 months, which was not significant when adjusting for all metabolites measured, but was significant when adjusting for relevant environmental and demographic exposures. Other metabolites measured were not associated with allergic sensitization or eczema, and maternal tryptophan metabolites were not associated with offspring rhinitis and wheeze.Conclusions and Clinical Relevance: Maternal tryptophan metabolism during pregnancy may influence the development of allergic sensitization and eczema in infants.Keywords
This publication has 49 references indexed in Scilit:
- Nutritional Aspect of Tryptophan MetabolismInternational Journal of Tryptophan Research, 2013
- Tryptophan metabolism, from nutrition to potential therapeutic applicationsAmino Acids, 2010
- Maternal meat and fat consumption during pregnancy and suspected atopic eczema in Japanese infants aged 3–4 months: The Osaka Maternal and Child Health StudyPediatric Allergy and Immunology, 2010
- Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposureAllergy, 2009
- Monocyte Chemoattractant Protein-1 (MCP-1): An OverviewJournal of Interferon & Cytokine Research, 2009
- MIG (CXCL9) is a more sensitive measure than IFN-γ of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccinesJournal of Immunological Methods, 2009
- Wheezing Rhinovirus Illnesses in Early Life Predict Asthma Development in High-Risk ChildrenAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenaseImmunology Letters, 2008
- NAD+ and Vitamin B3: From Metabolism to TherapiesThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Prevalence of eczema symptoms in the second year of lifeJournal of Allergy and Clinical Immunology, 2004